Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local
manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced
CAR T-cells (for example axicabtagene ciloleucel, a CD19 targeting commercially available CAR
T-cell) in patients with relapsed or refractory (R/R) DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
University Medical Center Groningen
Collaborator:
Stichting Hemato-Oncologie voor Volwassenen Nederland